Trials / Withdrawn
WithdrawnNCT00754104
Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors
A Phase 1, Open Label Study of ABT-869 in Combination With Tarceva in Subjects With Advanced Non-hematologic Malignancy
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study of ABT-869 in Combination with Tarceva in Subjects with Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-869 | 0.25 mg/kg. daily. |
| DRUG | Tarceva | 150mg, daily. |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2008-12-01
- First posted
- 2008-09-17
- Last updated
- 2011-01-19
Source: ClinicalTrials.gov record NCT00754104. Inclusion in this directory is not an endorsement.